Future research into non-Hodgkin lymphoma treatments needs to explore long-term outcomes and a better understanding biologic rationale for various different treatments, explained ECHELON-3 principal ...

It is a very rare complication. Richter’s syndrome occurs when CLL becomes a lymphoma, usually the non-Hodgkin’s type, and may develop suddenly. Typically, a diagnosis of CLL will already ...

Primary non-Hodgkin's lymphoma of the breast (PBNHL) is uncommon. There have been only a few reports of breast lymphoma in the radiology literature. In this case report, we describe mammographic ...

Lymphomas belong to the group of malignant diseases of the immune system and mainly affect the organs of the lymphatic system. Anaplastic large cell lymphoma (ALCL) belongs to the subgroup of ...

DelveInsight’s, “Non-Hodgkin Lymphoma Pipeline Insight 2025” report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in the Non-Hodgkin Lymphoma pipeline landscape.

A pooled analysis of individual data from 5 COG studies demonstrated that race/ethnicity has no significant effect on survival for children and AYAs with cancer receiving treatment on clinical trial.

Dr. Andrew M. Evens discussed the importance of differentiating AYA cancers from other age groups, specifically focusing on ...

The main illness examined was cases of non-Hodgkin lymphoma, a cancer known as NHL that starts in white blood cells and can affect the immune system. Read Next: 48 Hours with Marines and Soldiers ...

Lymphomas belong to the group of malignant diseases of the immune system and mainly affect the organs of the lymphatic system ...

Diagnosed incident cases of B-cell non-Hodgkin’s lymphoma (B-cell NHL) across the seven major markets (7MM) are expected to increase from 200,844 in 2023 to nearly 230,000 by 2033 at an annual ...

Another trial for non-Hodgkin's lymphoma using a similar IL18-armored CAR T cell product is currently enrolling patients. On the manufacturing side, the team is partnering with a Penn spinout ...

The ALCL-Relapse study was designed by the European Inter-Group for Childhood Non-Hodgkin Lymphoma as a prospective, stratified, multinational clinical trial and was opened for patients at trial sites ...